Intravesical Bacillus Calmette-Guérin (BCG) is the standard-of-care treatment for high-risk non-muscle invasive bladder cancer (HR-NMIBC). However, patients with BCG-unresponsive disease are unlikely to benefit from further BCG. To overcome BCG unresponsiveness, the addition of immune checkpoint inhibition (ICI) to BCG has been investigated in three recently randomized controlled trials: CREST, POTOMAC, and ALBAN, studying sasanlimab, durvalumab, and atezolizumab, respectively. While CREST and POTOMAC demonstrated improvements in event/disease-free survival (EFS/DFS), ALBAN was negative. Several potential explanations have been proposed for these discrepant findings. We propose an additional explanation: censoring. In the experimental arm, toxicity-related discontinuation may preferentially remove frailer patients, artificially enriching the remaining population for healthier individuals potentially biasing EFS or DFS. We explored censoring patterns across trials and conducted sensitivity analyses based on reconstructed Kaplan-Meier curves, and modifying only a few patients in POTOMAC and CREST eroded the EFS/DFS benefit as reported. The addition of immunotherapy to BCG significantly increases toxicity, and supports that some level of toxicity-related informative censoring might have differentially affected the three trials. Informative censoring may represent an important, underrecognized explanation for the inconsistent efficacy results reported across ICI plus BCG trials. More broadly, given the expanding use of immunotherapy in earlier disease settings and the reliance on time-to-event endpoints in open-label trials with differential toxicity, systematic attention to censoring mechanisms is essential for accurate interpretation.
European journal of cancer (Oxford, England : 1990). 2026 Apr 12 [Epub ahead of print]
Dries Develtere, Petros Tsantoulis, Timothée Olivier
Department of Urology, Jan Yperman Hospital, Ieper, Belgium., Department of Oncology, Geneva University Hospital, Geneva, Switzerland., Department of Oncology, Geneva University Hospital, Geneva, Switzerland. Electronic address: .